Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · 行业原文收录 · 来源发布：Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN4395 with tislelizumab, releasing two distinct immunosuppressive brakes on the anti-tumor immune response simultaneously. Paris - June 1, 2026 - Owkin, the Agentic AI company pione
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。